Israeli regenerative medicine company CollPlant Holdings Ltd. (TASE: CLPT) has set up a division that will focus on the further development of a collagen-based biological ink. CollPlant’s BioInk is intended for use in 3D printers that print organs and tissues using various printing technologies.
CollPlant CEO Yehiel Tal said, “Over the last several months, we have substantially ramped up our activities in the 3D printing field leveraging biological ink that we are developing based on our rhCollagen technology. The collagen protein is a keyattached also building block in connective tissues in the human body, and therefore is ideal for use as biological ink. In particular, our rhCollagen is especially suitable for use in humans, due to its superior homogeneity, its high safety profile and the fact that it does not cause an immunological reaction. We are currently developing a number of formulations of biological ink for various indications, and are working with several large international companies, with the aim of collaborating in the development of organs and tissues printing.”
According to the US Department of Health and Human Services, the number of people in the United States waiting for a transplant of a critical, life-saving organ such as a kidney, liver or pancreas, is approximately 118,000, and the organ transplant waiting list grows every year. BioInk is a significant component of the burgeoning 3D bioprinting market, which is expected to grow to approximately $1.8 billion by 2022, and to increase substantially as the printing technology, and all its components, continue to mature.
Published by Globes [online], Israel business news - www.globes-online.com - on May 14, 2017
© Copyright of Globes Publisher Itonut (1983) Ltd. 2017